SCHEMBL6480206

SCHEMBL6480206

Fc1ccc2oc3ccc(NCc4ccc5ccccc5n4)cc3c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGIR P43119 1/20 0.40
PTGDR Q13258 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
FAAH O00519 1/20 0.39
TERT O14746 2/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 4/20 0.37
ALDH1A1 P00352 4/20 0.37
RAB9A P51151 3/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
NOS1 P29475 1/20 0.36
HPGD P15428 2/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6496815 0.89 RAB9A (0.39) MAPTNPC1ALDH1A1RAB9AKDM4E
SCHEMBL6483367 0.80 BRD4 (0.43) NPC1ALDH1A1RAB9ASMN1; SMN2HPGD
SCHEMBL6765611 0.79 INSR (0.52) MAPTALDH1A1RAB9AKDM4ENOS1
SCHEMBL6495066 0.79 MAOA (0.50) MAPTNPC1ALDH1A1RAB9AKDM4E
SCHEMBL6496615 0.77 MAOB (0.49) GAAHPGDMEN1KMT2A
SCHEMBL6775761 0.77 EGFR (0.44) MAPTALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL6492265 0.76 BRD4 (0.45) MAPTNPC1ALDH1A1RAB9AKDM4E
SCHEMBL7250376 0.75 RAB9A (0.40) MAPTNPC1ALDH1A1RAB9AKDM4E
SCHEMBL6495652 0.75 MAPT (0.54) MAPTALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL6484551 0.74 USP10 (0.48) GAAHPGDLMNAHDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 PTGIR 4352/4885PTGDR 3754/4885PTGDR2 3316/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 PTGIR 4561/4885PTGDR 4078/4885PTGDR2 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.